Journey

What’s behind the AIDS narrative coming to a country near you?

Even as they seek to dump this pandemic in a shallow grave, they are already prepping the public for the next health scare — AIDS. ~ Off-Guardian

Why did Australia just order a shitload of HIV tests? Why are they calling for more “widescale” testing of HIV – even for those not in the known-risk group?

Moderna now has “HIV” vaccines in trial as of Feb 1st 2022, and on Feb 3rd 2022 there was a Journal publication of a “new highly virulent HIV variant circulating in the Netherlands”.

In Australia, we had our QLD COVID vaccine “cancelled” because people were testing positive for HIV (because they were “using” HIV material when making it). And all the adverse-events of vaccines getting auto-immune-like issues. Not to mention that it was known that the vaccines may increase risk of HIV – it’s happened before.

Not to forget that Luc Montagnier– HIV discoverer and virologist – wrote a paper saying that the spike-protein had HIV in it. There was also an (unconfirmed) rumour circulating that Luc Montagnier had told people to go take a HIV-test and be sitting down if they took the COVID booster, and he died 10 days later, on February 8th 2022, in between his Luxembourg parliament hearing in January 2022 warning people that ‘vaccines are poison‘ and his upcoming Grand Jury hearing set for February 14th 2022.

Sure he was an old man, but still bloody convenient don’t you think that he won the Nobel Prize for discovering HIV (so maybe the one person we might listen to if this HIV-narrative is untoward) and that he died 4 days before the Grand Jury proceeding (what was he going to reveal in that I wonder?).

My point being he was not exactly an old sick man laying on his death-bed at the time of death – he had been actively speaking against these vaccines – which he called poison, the mandates, and was interviewed all the way through 2020-2022 about the presence of evidence of HIV in the covid genome claiming COVID-19 that he said was likely man-made in a lab (and wrote a paper on it). He also was outraged they wanted to vaccinate children.

I know the pharma-funded fact-liars/checkers are refuting the claims that COVID-19 vaccines cause HIV but come on, you’d have to have blinders on to not see something untoward is happening to people’s immune systems after they get the jabs.

Let’s have a look at this crazy-media-frenzy and what’s going on behind the scenes and try and figure out why the new HIV narrative is here. Is it just to promote the Moderna-HIV vaccine? Just another way to keep the general-public in a constant state of fear/hysteria/psychosis? Or are they getting something that ‘looks like HIV” into us somehow – via the possible-bioweapon, geo-engineering, or injections, or is there some kind of new common immune-thing going on – and if so, what can we do to increase our white-blood cell count or whatever we need to do to figure out a way to avoid their constant-push for chasing around the population with regular billion-dollar injections for their money-making scams and social credit system.

Plus I’m skeptical about the whole HIV/AIDS history – so much. And if it really is spread by multi-partner sex, then how do we get a more rapidly-spreading HIV virus after 2 years of constant lockdowns – where’s the multi-partner sex if you can’t leave your house?

/ End random brain dump

Jun 14, 2022 Nature article published “Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry” ^{(01)Mannar D, Leopold K, Subramaniam S. Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry. Sci Rep. 2021 Jun 14;11(1):12448. doi: 10.1038/s41598-021-91746-7. PMID: 34127709; PMCID: PMC8203731. … Click for full citation}

March 2022

Mar 22, 2022 Dr. Catherine Kibirige develops HIV tests to advance vaccine and cure research

Dr. Catherine Kibirige is a research associate at Imperial College London in the Human Immunology Laboratory. She decided as a teenager that her career would encompass HIV research. 

“We’d just come out of a civil war, so it was very devastating. On top of all the issues with the civil war, there’d been famine, there’d been desolation and then we had HIV,” said Kibirige. “It really had a huge impact on us as a nation and I lost a lot of close relatives. I knew I wanted to be involved in HIV research.” 

“We need to get to the point now where we’re actually making our own reagents, doing our own vaccine research and not having to import everything.” ^{(02) Mar 22, 2022 Dr. Catherine Kibirige develops HIV tests to advance vaccine and cure research}

1. I find this article relevant in that it covers all things-the “Black Lives Matter” narrative, which only serves to divide and discriminate, and by having that movement it creates an “us and them” mentality, conscious or not. Don’t people see that? We are all flowers from the same garden, and creating a ‘movement’ like this, creates a victim-mentality instead of a united one.
2. John Hopkins
3. The fact that countries are still relying on CDC for reagents (so no independent reagents- becomes relevant the more you dig)
4. The testing of vaccines on third-world nations
5. War, famine, and ‘then’ the presence of a HIV epidemic.

Mar 16, 2022 Moderna (MRNA) Early-Stage HIV Vaccine Study Begins, Stock Up ^{(03) Moderna (MRNA) Early-Stage HIV Vaccine Study Begins, Stock Up – Yahoo – 16 March 2022}

Moderna, Inc. MRNA announced that the first participant has been dosed in a phase I study (HVTN 302) evaluating its mRNA-based human immunodeficiency virus (“HIV”) trimer vaccine candidate, mRNA-1574.

The phase I study, which is being sponsored by a division of the National Institute of Allergy and Infectious Diseases (NIAID), will evaluate the safety and immunogenicity of mRNA-1574 in nearly 100 participants not infected with HIV aged between 18 and 55 years. The premise of starting this study is that this trimer vaccine is not only well-tolerated and safe in HIV-negative participants but also generates neutralizing antibodies against the virus.

1. This mainstream article wrongly states that “Moderna has only one approved product in its portfolio—its COVID-19 vaccine.”
   • NO. Moderna has never brought a vaccine to market and they’re vaccine is not “approved” – it only has “Emergency-Use” Authorization and “Provisional” because the ‘product’ is still in clinical trials and the safety data is unknown until the trial is complete and the data is reviewed.
2. The article also states that HIV causes AIDS – a claim that has been constantly debated by scientists – even by those who ‘discovered it’. When are we going to get the final answer and the truth about this rather than stay in this constant lie of “everybody knows”?
   • If “everybody knows”, there would be nothing to debate, and yet, here we are.
     • Probably not going to ever get the answer while hundreds of thousands of charities, government organizations, and pharmaceutical industries, need it to be true to receive billions of dollars in funding.
     • There’s a financial benefit to keep this story going. There’s no benefit to the scientists’ speaking out. It sounds frighteningly familiar.

Mar 14, 2022 Anthony Fauci – NIH – “excited about mRNA HIV vaccines”

“Finding an HIV vaccine has proven to be a daunting scientific challenge,” said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, in a statement on Monday. “With the success of safe and highly effective COVID-19 vaccines, we have an exciting opportunity to learn whether mRNA technology can achieve similar results against HIV infection.” ⁽⁰⁴⁾ March 14, 2022 NIH launches clinical trial of three mRNA HIV vaccines – NIH.gov

HVTN 302 study is available on ClinicalTrials.gov using the identifier NCT05217641 ⁽⁰⁵⁾ March 14, 2022 HVTN 302 study is available on ClinicalTrials.gov using the identifier NCT05217641

1. Dude is invested in Moderna. So dude should not be promoting said vaccines at all due to massive conflict of interest and financial gain. Let alone NIAID worked closely with Moderna to design its vaccine, and Warp Speed gave the firm $1.5 billion for related R&D and efficacy trials – despite never before bringing a vaccine to market.
2. Dude mentioned “safe and highly effective COVID-19 vaccines” – you mean the same ones that are harming everyone, and don’t work to prevent transmission, and have more vaccinated than not in hospitals & death, and puts those who take it at higher risk of infection? Those vaccines?
3. So is he implying that he wants “similar results” of ineffectiveness and harm? Or does he just have dollar-signs in his eyes? Either way. Up yours mate.
4. Dude is corrupt and has a long fraudulant history, in particular with HIV/AIDS, but now with COVID.

ClinicalTrials.gov Identifier: NCT05217641

ClinicalTrials.gov Identifier: NCT05217641

Mar 11, 2022 Expanding Efforts and Support to Respond to the HIV and COVID-19 Intersecting Pandemics

“Increased support needed for a coordinated global HIV and COVID-19 response”

“Immunocompromised persons with persistent COVID-19 could be the origin of SARS-CoV-2 variants of concern (VOC).”

“The current approach is costing countries their economies and reversal of sustainable development goals.”

“The investigative community must develop clinical trials to test therapeutic interventions for immunosuppressed patients with persistent COVID-19 so that guidelines can then be developed. “

“With intersecting pandemics, we must reevaluate our approach in responding to HIV and COVID-19 through two major components: global immunization and enhanced services to people living with and at risk for exposure to HIV,” said Dr. Larry Corey, professor in the Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Research Center.  ⁽⁰⁶⁾ Corey L, Corbett-Detig R, Beyrer C. Expanding Efforts and Support to Respond to the HIV and COVID-19 Intersecting Pandemics. JAMA. Published online March 11, 2022. doi:10.1001/jama.2022.3517 ⁽⁰⁷⁾ Mar 16, 2022 article “Increased support needed for a coordinated global HIV and COVID-19 response” – MedicalExpress.com

1. Skeptical of a new paper lumping HIV & COVID together as “intersecting pandemics“
2. Skeptical of calling for more HIV-testing.
3. Skeptical of calling immunocompromised people with “persistent covid” a candidate to potentially blame for variants of concern.
   • (Especially since you referenced your own paper that you are first author of) ⁽⁰⁸⁾ Corey L, Beyrer C, Cohen MS, Michael NL, Bedford T, Rolland M. SARS-CoV-2 Variants in Patients with Immunosuppression. N Engl J Med. 2021 Aug 5;385(6):562-566. doi: 10.1056/NEJMsb2104756. PMID: 34347959; PMCID: PMC8494465.
4. Sustainable development goals is brought up
   • Wow – so HIV, COVID, and Climate-Change in the same paper…
   • or Maybe I’m having a “Pfffffffffffft Day!”
5. Skeptical of the wording used about Omicron to infer that this is an urgent need.
6. Skeptical of the calling COVID-19 vaccines “highly efficacious”
   • (are you kidding me – are we on the same planet?)
   • Oh I see now – you are listed as one of the authors of the Moderna Efficacy & Safety Trials – wow, you can’t make this up – I have so many questions for people involved in these ridiculous trials. ⁽⁰⁹⁾Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, … Click for full citation ⁽¹⁰⁾El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann … Click for full citation ⁽¹¹⁾ A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 – ClinicalTrials.gov ⁽¹²⁾ Moderna COVE Study – modernatx.com
     • Were you on board with the unblinding of the trial participants so that noone on the planet has any access to data that we can rely upon or compare?
     • And is death or permanent injury considered an “acceptable safety profile”?
     • And that there were more deaths in the vaccinated than placebo in the Supplementary Data but not listed in the final paper?
     • Did you speak to any of the patients who suffered or who left the study – were they real to you? or were they just numbers on a spreadsheet?
     • Are you cool with how quickly they rolled-it-out to the world with just that small amount of data?
     • Are you cool with mandating these experimental jabs even though they are still in the initial trial?
     • Are you on board with them omitting covid-19 deaths after vaccination if they occurred less than 14 days after 2nd dose? If they only reported the data Starting 14 Days After Second Injection – how could you tell if the dosages didn’t actually cause their illnesses in the first place – what data did you have for that?
     • What care/advice did they give the study participants when they ‘got COVID’?
     • I have more questions.
7. Skeptical of the calling for the expansion of key donor programs and more funding.
8. Skeptical of the calling for MORE covid surveillance
   • (MORE Surveillance!?)
9. Skeptical of authors conflicts of interest. Grants from NIAID
   • (Really – Anthony Fauci’s baby? The same company that gave grants to EcoHealth Alliance that ended up at the Wuhan lab – of which the “virus” could’ve originated / been developed in the first place?)
10. And you get funding from CDC, NIH, and you’re a senior liaison to the COVID Vaccine Prevention Network
    • (so you basically work for Fauci, conduct COVID-19 vaccine trials, and develop HIV/AIDS vaccines. Ok. Sure. Let’s listen to every word you say about safety.)

Feb 2022

Feb 9, 2022 We need “More widespread testing of all people, regardless of preconceived assumptions about risk”

The Guardian - Feb 9 2022

Terrence Higgins Trust - Wikipedia

Ian Green - Chief Executive

ZoomInfo - Terrence Higgins Trust

The Terrence Higgins Trust Financial History

We need for a “new strategy” to combat HIV. “Continuing to solely target those traditionally most at risk won’t work,” he said. The answer, according to Ian Green of the Terrence Higgins Trust, is more widespread testing of all people, regardless of preconceived assumptions about risk. ⁽¹³⁾ Feb 9, 2022 – The Guardian – HIV now infects more heterosexual people than gay or bisexual men – we need a new strategy Ian Green

1. Another conflict of interest writing a piece calling for widespread HIV-testing when you are the Chief Executive of UK’s largest HIV charity that raises millions of dollars in art auctions, who has over 30 HIV testing sites
2. I hope you truly are doing good work and that a mainstream article calling for more widespread HIV testing of everyone regardless of risk-factors is coming from a good-hearted space.
3. I’m just personally now so very sceptical of “charities for diseases” at first-glance because the whole pharmaceutical-industry is corrupt and lots of charities are making a killing.
4. Not calling you guys out for anything nefarious, just will take with a grain-of-salt any opinion piece written by large-£25m-charities when the result of writing such an article would mean more financial gain – either by the testing or by raising more revenue – so could be more of an advertisement than an informative article.
5. Plus, I am personally very sceptical of the the whole HIV/AIDS history, the testing, the origin, the scare-mongering from Fauci saying you can “catch it from your kids” when it first came out – and the whole pharmaceutical scare-marketing campaign that I grew up with, and the drugs that killed more people than it saved.

Feb 3, 2022 A highly virulent variant of HIV circulating in the Netherlands ⁽¹⁴⁾ Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A,  et al. A highly virulent variant of HIV-1 circulating in the Netherlands. Science. 2022 Feb 4;375(6580):540-545. doi: 10.1126/science.abk1688. Epub 2022 Feb 3. PMID: 35113714.

Abstract

We discovered a highly virulent variant of subtype-B HIV-1 in the Netherlands. One hundred nine individuals with this variant had a 0.54 to 0.74 log₁₀ increase (i.e., a ~3.5-fold to 5.5-fold increase) in viral load compared with, and exhibited CD4 cell decline twice as fast as, 6604 individuals with other subtype-B strains. Without treatment, advanced HIV-CD4 cell counts below 350 cells per cubic millimeter, with long-term clinical consequences-is expected to be reached, on average, 9 months after diagnosis for individuals in their thirties with this variant. Age, sex, suspected mode of transmission, and place of birth for the aforementioned 109 individuals were typical for HIV-positive people in the Netherlands, which suggests that the increased virulence is attributable to the viral strain. Genetic sequence analysis suggests that this variant arose in the 1990s from de novo mutation, not recombination, with increased transmissibility and an unfamiliar molecular mechanism of virulence.

• Before I even start. Over 1,000 authors, really? Normally, because I’ve become so skeptical, I would look into each of you, but I don’t want to spend the rest of the year looking you all up to see where all your conflicts of interests are.

PMID: 35113714 DOI: 10.1126/science.abk1688

PMID: 35113714 DOI: 10.1126/science.abk1688

Feb 1, 2022 Clinical Trial to test Moderna’s mRNA HIV Experimental Vaccine(s) – Phase 1

ClinicalTrials.gov Identifier: NCT05217641

ClinicalTrials.gov Identifier: NCT05217641

A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants ⁽¹⁵⁾ Feb 1, 2022 A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants – ClinicalTrials.gov

Each participant will be randomly assigned to one of six groups each receiving three vaccinations of one of the experimental vaccines. The first three groups (18 participants each), called Group A, will receive intramuscular injections of 100 micrograms (mcg) of their assigned vaccine candidate at the initial visit, at month two and again at month six. Participants in Group A will be evaluated two weeks after initial vaccination to ensure safety criteria have been met. If so, the remaining three groups of 18 participants each (Group B) will be vaccinated with 250 mcg of the assigned investigational vaccine, followed by injections two and six months after the initial vaccination. 

Feb 10, 2022 Prince Harry has urged people to “know your status” and “go and get a test” for HIV. – BBC ⁽¹⁶⁾ Feb 10 2022 – BBC – Know your status and get an HIV test, says Prince Harry

1. Hardly unusual being that he took over the role of being an AIDS Ambassador like his mum.
2. I include it only because it’s going viral and noone seems to mention that he’s an AIDS Ambassador.

Feb 7, 2022 Identification of fast-spreading HIV variant provides evidence of urgency to halt the pandemic and reach all with testing and treatment – United Nations Press Release

Around 10 million people living with HIV are still not on antiretroviral therapy

GENEVA, 7 February 2022—Newly published research from the Netherlands has revealed the existence of a more transmissible and damaging variant of HIV. People living with the newly revealed HIV subtype experience double the rate of immune system decline (CD4 count), have higher HIV viral loads (amount of virus in the blood) and are vulnerable to developing AIDS two to three times faster after diagnosis than if they were living with other strains of the virus. The study, led by researchers from the University of Oxford’s Big Data Institute, was the first to discover this highly virulent variant of the subtype-B of HIV. The study also revealed that the variant has been circulating in the Netherlands for years and remains receptive to HIV treatment.

The HIV pandemic continues to take a life every minute and scientists have long worried about the evolution of new, more transmissible, variants of HIV. This newly identified variant does not represent a major public health threat but underscores the urgency of speeding up efforts to halt the HIV pandemic.

UNAIDS unites the efforts of 11 UN organizations—UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO and the World Bank —and works closely with global and national partners towards ending the AIDS epidemic by 2030 as part of the Sustainable Development Goals.

Read the full press release ⁽¹⁷⁾Feb 7, 2022 Identification of fast-spreading HIV variant provides evidence of urgency to halt the pandemic and reach all with testing and treatment – United Nations Press Release – UNAIDS.org

1. Now it’s a HIV “pandemic“?
2. Specifically highlighting “... not on ‘antiretroviral therapy‘” in the sub-title.
3. The UN, WHO and World Bank making ‘ending the AIDS epidemic by 2030 as part of the Sustainable Development Goals”.

Jan 2022

Jan 31, 2022 – First patients vaccinated in clinical trial of HIV experimental vaccine that uses Moderna’s mRNA technology ⁽¹⁸⁾ Jan 31, 2022 – First patients vaccinated in clinical trial of HIV experimental vaccine that uses Moderna’s mRNA technology – CNN Health

Jan 28, 2022 – Moderna launches clinical trial for HIV vaccine that uses mRNA technology ⁽¹⁹⁾Jan 28, 2022 Moderna launches clinical trial for HIV vaccine that uses mRNA technology – ABC News

Moderna announced Thursday that it’s launched early-stage clinical trials of an HIV mRNA vaccine.

The biotechnology company has teamed up with the nonprofit ​​International AIDS Vaccine Initiative to develop the shot, which uses the same technology as Moderna’s successful COVID-19 vaccine.

The first participants in the Phase I trial were given doses at George Washington University School of Medicine and Health Sciences in Washington, D.C., according to a company statement.

Jan 27, 2022 – IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through Mrna Technology ⁽²⁰⁾ IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through Mrna Technology – Moderna Company Statement

Phase 1 trial aims to build on response seen in proof-of-concept trial

CAMBRIDGE, MA and NEW YORK, NY / ACCESSWIRE / January 27, 2022 / IAVI, the nonprofit scientific research organization, and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C.

The Phase 1 trial, IAVI G002, is designed to test the hypothesis that sequential administration of priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can induce specific classes of B-cell responses and guide their early maturation toward broadly neutralizing antibody (bnAb) development. The induction of bnAbs is widely considered to be a goal of HIV vaccination, and this is the first step in that process. The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna’s mRNA technology

The sites will enroll 56 healthy, HIV-negative adult volunteers. Forty-eight participants will receive one or two doses of eOD-GT8 60mer mRNA Vaccine (mRNA-1644), with 32 of them receiving the boost Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core). An additional eight volunteers will receive the boost immunogen alone. Participants will be monitored for safety for six months after last vaccination. Participants’ immune responses to the vaccine candidates will be examined in molecular detail to evaluate whether the targeted responses were achieved.

Jan 10, 2022 Dr Shankara Chetty – Spike Protein – Engineered Slow-Death Poison

Dr Shankara Chetty is a Medical Doctor in Port Edward, South Africa who has treated over 5000+ Covid patients with zero hospitalisations or deaths, says the spike protein (from covid-illness and the vaccine) is a well-engineered, weapons-grade pathogen / slow-death poison. ⁽²¹⁾ Dr Shankara Chetty: Spike Protein Is A Well-Engineered Slow-Death Poison https://pennybutler.com/shankara-chetty-spikeprotein-poison/

1. This toxin in the longterm is going to get people with pre-existing illness, to have those illnesses “exacerbated” – it has bits of prion in it, it has bits of HIV-protein in it, it is definitely “engineered”.
2. So people with cancers are going to have their cancers flare-up – and we’ll say “they died of the cancer”.
3. People with vessel injuries or pre-disposition like our diabetics and hypertensives are going to have strokes and heart-attacks, and the rest at varying times, and we will attribute those to their pre-existing conditions.
4. People are going to develop over time auto-immune conditions, the diversity of which will never be addressed by any pharmaceutical intervention, because they are far too targetted – and so we have a rough road coming.

See also:

• Dr Shankara Chetty: Spike Protein Is A Well-Engineered Slow-Death Poison
• 7000+ C19 Patients (0 Deaths). Cause: “Allergen To Spike Protein Man-Made Poison” [Testimony]

Jan 1, 2021 Similarities and differences between HIV and SARS-CoV-2 ⁽²²⁾Illanes-Álvarez, Francisco et al. “Similarities and differences between HIV and SARS-CoV-2.” International journal of medical sciences vol. 18,3 846-851. 1 Jan. 2021, doi:10.7150/ijms.50133 … Click for full citation

Dec 2021

Dec 23, 2021 “The UBUNTU Study” Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern (CoVPN3008) ⁽²³⁾ CoVPN 3008: UBUNTU Study – coronaviruspreventionnetwork.org – yep, Fauci’s baby ⁽²⁴⁾ What is the UBUNTU study? – UbuntuStudy.org ⁽²⁵⁾ Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern (CoVPN3008) – ClinicalTrials.gov

The UBUNTU Study is a randomized efficacy study of a COVID-19 mRNA vaccine in Eastern and Southern Africa for those living with HIV &/or have one or more conditions associated with increased risk of severe COVID-19 (such as pregnancy, diabetes, obesity, heart or kidney disease, and cancer). This study is also known as “CoVPN 3008.” The study is being done by the COVID-19 Prevention Network (CoVPN). The study vaccine was developed by the company ModernaTX and is known as the Moderna COVID-19 mRNA vaccine. The study will enrol about 14 000 people at approximately 54 research clinics.

The Moderna COVID-19 vaccine used in this study is under an Emergency Use Authorization in the United States. This vaccine is also on the Emergency Use Listing by the World Health Organization, which recommends its use to prevent COVID-19 disease. It has been given to more than 70 million people and has been shown to be over 90% effective in preventing COVID-19 illness caused by the strains of the virus in the US and Europe. 

The UBUNTU study is a research study evaluating the Moderna COVID-19 mRNA vaccine. We already know that this vaccine works in preventing COVID-19 disease including severe COVID-19.

 We want to know how many doses of vaccine are needed for protection against COVID-19 for adults living with HIV and adults with existing health conditions that may put them at risk for severe COVID-19. We also want to know if people who have already had COVID-19 (and likely have some immunity) need as many vaccine doses as other people to obtain strong protection from COVID-19. 

1. Firstly, “has been shown to be over 90% effective”?
   • (What planet are we talking about? I must be in another dimension from their vaccine-marketing team.)
2. Secondly, how dare they use the word UBUNTU in their name.
   • The brainwashing/propaganda tactics these pharma-criminals stoop to is just beyond – there’s no place sacred they won’t tarnish with their marketing filth. Are they trying to get people to trust them? Of course they are. And Ubuntu is a way for sure.
3. Study is being conducted by the COVID-19 Prevention Network (CoVPN).
   • Think Fauci. Think NIAID. Think NIH.
4. Vaccine is Moderna.
   • Think Fauci. Think NIAID. Think NIH. Think billions of dollars provided to them even though they’ve never brought a vaccine to market.
5. The only warning given to the participants is the “extremely small risk” of developing Myocarditis and Pericarditis, which they say this reaction is very, very low and that when it happens, it most often occurs in men less than 20 and that the symptoms don’t last long and most get better.
   • Oh Wow. Have you not spoken to any of the victims at all? Or do you just play around on your computer, and make them disappear.
     • My guess is you have dollar-signs in your eyes and they have blinded your conscience, and this is just another marketing ploy to try and get people to trust you.
       • You continually undermine that trust when you’re not completely transparent about the serious side-effects and how some of those who developed these 2 conditions are being told they will be on life-long drugs – that there are over 1000 peer reviewed case-reports already published on adverse reactions – which include “death” – and pages to be warned about, let alone the increased-risk of illness shortly following the jab… ⁽²⁶⁾ Over 1,000 studies published in peer-reviewed medical journals say the vaccines are dangerous https://www.saveusnow.org.uk/covid-vaccine-scientific-proof-lethal/
         • … and the most important…
         • COVID-19 is treatable and severity can be averted with good health practices and early-treatment – not a needle.

Nov 29, 2021 HIV Self-Tests Soon Available in Australian Pharmacies ⁽²⁷⁾ HIV Self-Tests Soon Available in Australian Pharmacies https://www.theepochtimes.com/hiv-self-tests-soon-available-in-australian-pharmacies_4129954.html

24 Nov 2021 The NSW HIV Strategy 2021-2025 aims to achieve a 90% reduction in the rate of preventable HIV infection to achieve the virtual elimination of HIV transmission in NSW. In 2021-22 the NSW Government is investing $23.7 million in services to strengthen HIV testing, treatment, and prevention.  ⁽²⁸⁾ 24 Nov 2021 Prevention, testing, and treatment – The key to NSW HIV elimination – https://www.health.nsw.gov.au/news/Pages/20211124_00.aspx

See also:

• NSW HIV Strategy 2021-2025 ⁽²⁹⁾ NSW HIV Strategy 2021 – 2026 Quarter 1 2021 Data Report https://www.health.nsw.gov.au/endinghiv/Publications/q1-2021-nsw-hiv-data-report.pdf

Oct 2021

Oct 19, 2021 NIH, Bill and Melinda Gates Foundation Collaborate to Develop Gene-Based HIV Treatment ⁽³⁰⁾ NIH, Bill and Melinda Gates Foundation Collaborate to Develop Gene-Based HIV Treatment https://www.ajmc.com/view/nih-bill-and-melinda-gates-foundation-collaborate-to-develop-genebased-hiv-treatment

The Gates Foundation and the National Institute of Allergy and Infectious Diseases (NIAID), a part of the NIH, are both currently exploring gene-based treatments for HIV, together with other therapies, and they noted that this collaboration will allow them to intensify their research, coordinate on their efforts, and accelerate studies into early clinical trials to test promising interventions.

The National Institutes of Health (NIH) has announced plans to invest at least $100 million over the next 4 years to develop gene-based therapies for 2 diseases: HIV and sickle cell disease. The Bill and Melinda Gates Foundation will also contribute $100 million to the goal of advancing these potential cures, with an aim toward providing affordable, globally available treatment that will be accessible to patients in low-resource settings.

Oct 16, 2021 Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272

“Here, we report the case of a man living with HIV who, having previously achieved stable viral suppression, experienced a transient period of non-suppressible viremia after receiving a dose of COVID-19 vaccine.” ⁽³¹⁾Bozzi G, Lombardi A, Ludovisi S, Muscatello A, Manganaro L, Cattaneo D, Gori A, Bandera A. Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272. Int J Infect Dis. 2021 Dec;113:125-126. doi: 10.1016/j.ijid.2021.10.021. Epub … Click for full citation

In April 2021, the patient, by then suppressed for more than 6 months, with a negative clinical history and negative anti-N antibodies for SARS-CoV-2, received the first dose of mRNA-1273 vaccine (Moderna Biotech). The vaccine was also well tolerated; the patient did not report any systemic side effect. Twenty-eight days later, before receiving his second dose of vaccine, which was scheduled on the same day, blood samples were acquired in the outpatient HIV clinic for quarterly routine bloodwork. Fourteen days after the increase (and the second vaccine dose), a new bloodwork was obtained and his VL was suppressed again.

Previous studies have found transient increases in HIV VL after vaccination for influenza, Streptococcus pneumoniae, and hepatitis B virus among others, whereas others have shown no effect. When observed, most VL increases occurred 7–14 days after vaccination.

A recent randomized controlled trial compared the effects of several vaccination schedules versus placebo in suppressed PLWH and did not find effects on plasma RNA, but showed an increase in HIV cell-associated RNA, CD4+ and CD8+ T-cell activation markers, as well as HIV-specific CD8+ responses.

Furthermore, a recent work showed CD4+ T-cell cross-reactivity between seasonal coronaviruses and SARS-CoV-2 in vaccine recipients. However, the interplay of mRNA vaccines, the immune system, and latent HIV infection is yet to be thoroughly understood. ⁽³²⁾Woldemeskel BA, Garliss CC, Blankson JN. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. J Clin Invest. 2021 May 17;131(10):e149335. doi: 10.1172/JCI149335. PMID: 33822770; PMCID: … Click for full citation

Further studies are needed to evaluate whether novel mRNA vaccines have the potential to perturb the latent HIV reservoir, which would be beneficial for the design of future eradication strategies.

Sept 2021

The WEF is promoting Moderna’s human trials for an HIV “vaccine” using mRNA technology

mRNA technology could provide the breakthrough.

Learn more about the search for an HIV vaccine: https://t.co/BiFk1pRS51 pic.twitter.com/ORkM0DiD56

— World Economic Forum (@wef) September 27, 2021

July 2021

July 16, 2021 WHO publishes new Consolidated HIV guidelines for prevention, treatment, service delivery & monitoring ⁽³³⁾ WHO publishes new Consolidated HIV guidelines for prevention, treatment, service delivery & monitoring https://www.who.int/news/item/16-07-2021-who-publishes-new-consolidated-hiv-guidelines-for-prevention-treatment-service-delivery-monitoring ⁽³⁴⁾Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach https://www.who.int/publications/i/item/9789240031593 | PDF of Guidelines 10.4 Mb … Click for full citation

July 13, 2021 Paper – HIV and Messenger RNA (mRNA) Vaccine

A paper that reads more like a pharmaceutical mRNA cheer-leading advertisement is published, touting the advantages of mRNA vaccines and the “mainstream version of HIV history”. ⁽³⁵⁾ Khalid, K., Padda, J., Khedr, A., Ismail, D., Zubair, U., Al-Ewaidat, O. A., Padda, S., Cooper, A. C., & Jean-Charles, G. (2021). HIV and Messenger RNA (mRNA) Vaccine. Cureus, 13(7), e16197. https://doi.org/10.7759/cureus.16197

June 2021 – Dr. Richard Fleming shares Luc Montagnier’s discovery that spike proteins may contain genetic sequences from HIV…

October 2020

Oct 20, 2020 – Researchers Warn Some Covid-19 Vaccines Could Increase Risk Of HIV Infection ⁽³⁶⁾ Researchers Warn Some Covid-19 Vaccines Could Increase Risk Of HIV Infection https://www.forbes.com/sites/roberthart/2020/10/20/researchers-warn-some-covid-19-vaccines-could-increase-risk-of-hiv-infection/?sh=2853eee83740

Some of the Covid-19 vaccines currently in development could increase the risk of acquiring HIV, warned a group of researchers in the The Lancet medical journal Monday, potentially leading to an increase in infections as vaccines are rolled out to vulnerable populations around the world. 

• The researchers warn of a “cautionary tale” from efforts to create an HIV vaccine over a decade ago, where a promising vaccine candidate actually increased the risk of some men catching the virus.
• The vaccine made use of a modified virus — called adenovirus 5 (Ad5) — as a vector to transport some of HIV’s genetic material into the body. 
• Exactly how the vaccine increased the risks of HIV transmission is unknown, but a conference convened by the National Institutes of Health recommended against further use of Ad5 as a vector in HIV vaccines
  • (Dr. Anthony Fauci was lead author of the paper outlining this position.)  

Ad5 is used as a vector in some Covid-19 vaccines —  Science identifies four such candidates that are currently undergoing clinical trials in various countries around the world, including the U.S., with two in large scale phase 3 trials ongoing in Russia and Pakistan. 

The researchers stressed the need to understand the role Ad5 might play in increasing the risks of HIV in vulnerable populations before developing and deploying vaccines using the vector, adding that informed consent documents should reflect the “considerable literature” on the risk of HIV acquisition with Ad5 vectors. 

FURTHER READING

• Could certain COVID-19 vaccines leave people more vulnerable to the AIDS virus? (Science)
• Use of adenovirus type-5 vectored vaccines: a cautionary tale (The Lancet) ⁽³⁷⁾ Buchbinder SP, McElrath MJ, Dieffenbach C, Corey L. Use of adenovirus type-5 vectored vaccines: a cautionary tale. Lancet. 2020;396(10260):e68-e69. doi:10.1016/S0140-6736(20)32156-5
• Increased Risk Of HIV Adenovirus Type-5 C19 Vaccines (My Post with the Highlights)

April 2020

April 19, 2020 New page appears on World Health Organization Summary of the global HIV epidemic ⁽³⁸⁾ April 19, 2020 – World Health Organization creates new page for HIV Epidemic https://www.who.int/data/gho/data/themes/hiv-aids ⁽³⁹⁾ Archive.org – https://www.who.int/data/gho/data/themes/hiv-aids

Jan 31, 2020 – Article published on a Friday to the pre-print server. ^{(40)Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag Prashant Pradhan, Ashutosh Kumar Pandey, Akhilesh Mishra, Parul Gupta, Praveen Kumar Tripathi, Manoj … Click for full citation}

Feb 2, 2020 – Article was withdrawn on the Sunday. ^{(41) Withdrawn Notice “Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag” https://www.biorxiv.org/content/10.1101/2020.01.30.927871v2}

Abstract

We are currently witnessing a major epidemic caused by the 2019 novel coronavirus (2019-nCoV). The evolution of 2019-nCoV remains elusive. We found 4 insertions in the spike glycoprotein (S) which are unique to the 2019-nCoV and are not present in other coronaviruses. Importantly, amino acid residues in all the 4 inserts have identity or similarity to those in the HIV-1 gp120 or HIV-1 Gag. Interestingly, despite the inserts being discontinuous on the primary amino acid sequence, 3D-modelling of the 2019-nCoV suggests that they converge to constitute the receptor binding site. The finding of 4 unique inserts in the 2019-nCoV, all of which have identity /similarity to amino acid residues in key structural proteins of HIV-1 is unlikely to be fortuitous in nature. This work provides yet unknown insights on 2019-nCoV and sheds light on the evolution and pathogenicity of this virus with important implications for diagnosis of this virus.

June 1 2019 NSW Health orders all Hospital Admissions with flu symptoms or fever to get HIV-tested

In Australia, NSW Chief Health Officer Dr Kerry Chant orders all doctors at hospitals to test all patients that present with cold and flu symptoms for HIV without written informed consent. ^{(42) NSW Health – Testing for HIV in Emergency Departments H19/54139-1 https://aci.health.nsw.gov.au/__data/assets/pdf_file/0006/496689/CHO-letter-to-CEs-re-ED-HIV-Testing_June-2019.pdf}

1. Since when does a fever of unknown origin warrant a HIV test? ^{(43) The three most common causes of fever of unknown origin (FUO) are infection, neoplasia, and connective tissue disease.  https://aci.health.nsw.gov.au/networks/eci/clinical/clinical-tools/infectious-diseases/fever-of-unknown-origin}
2. No longer require patient’s written consent? (citing this requirement as “outdated”)

Aug 1, 2004 Researchers in Beijing back in 2004 publish a paper: ⁽⁴⁴⁾Nie, Yuchun et al. “Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression.” Biochemical and biophysical research communications vol. 321,4 (2004): 994-1000. … Click for full citation

“we incorporated the humanized SARS-CoV spike (S) glycoprotein into HIV particles to generate a highly infectious SARS-CoV pseudotyped virus.”

1980s Robert C Gallo pretended to discover lab-engineered HIV-1 during the 1980s. ^{(45) How the discovery of HIV led to a transatlantic research war https://www.pbs.org/newshour/health/how-the-discovery-of-hiv-led-to-a-transatlantic-research-war}

1997-2016 Patents by Inventor Anthony S. Fauci ^{(46) JUSTIA Patents Patents by Inventor Anthony S. Fauci https://patents.justia.com/inventor/anthony-s-fauci}

Anthony S. Fauci has filed for patents to protect the following HIV-related inventions.

Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin
Patent number: 9896509
Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
Type: Grant
Filed: August 3, 2016
Date of Patent: February 20, 2018
Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

Use Of Antagonists Of The Interaction Between Hiv Gp120 And A4b7 Integrin
Publication number: 20160333097
Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
Type: Application
Filed: August 3, 2016
Publication date: November 17, 2016
Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv
Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin
Patent number: 9441041
Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
Type: Grant
Filed: September 21, 2015
Date of Patent: September 13, 2016
Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

Use Of Antagonists Of The Interaction Between HIV Gp120 And A4b7 Integrin
Publication number: 20160075786
Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
Type: Application
Filed: September 21, 2015
Publication date: March 17, 2016
Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human Serv
Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

Immunoconjugates Comprising Cd4 And Immunoglobin Molecules For The Treatment Of HIV Infection
Publication number: 20090285815
Abstract: Nucleic acids encoding recombinant CD4-fusion proteins are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C terminus of the heavy chain of an IgA antibody or a tailpiece from a C terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.
Type: Application
Filed: March 21, 2008
Publication date: November 19, 2009
Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci

HIV related peptides
Patent number: 6911527
Abstract: This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.
Type: Grant
Filed: January 7, 2000
Date of Patent: June 28, 2005
Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
Inventors: Giuseppe Scala, Xueni Chen, Oren J. Cohen, Anthony S. Fauci

Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
Publication number: 20040265306
Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody or a tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.
Type: Application
Filed: July 27, 2004
Publication date: December 30, 2004
Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci

See also:

• The Fauci/COVID-19 Dossier
• Posts tagged Fauci
• The REAL Anthony Fauci